Jeffrey W. Albers appointed President of Algeta US
Mr. Albers joins Algeta from Genzyme (Sanofi), where he spent the past seven years in senior commercial and corporate development positions, most recently as Vice President, US Hematology & Oncology Business. In this role, Mr. Albers had P&L responsibility for a USD 250m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil® and integrating Campath® and Leukine® into the portfolio (acquired from Bayer in 2009) involving a significant field force restructuring. After the acquisition of Genzyme by Sanofi he represented Genzyme on the US Oncology Integration Team. Prior to Genzyme, he spent five years (2000-2005) as an attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. Mr. Albers has a B.Sc. in Marketing from Indiana University, and a law degree (J.D.) and MBA from Georgetown University (Washington, DC).
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.